Isoquercetin and Zafirlukast Cooperatively Suppress Tumor Growth and Thromboinflammatory Signaling in a Xenograft Model of Ovarian Cancer.

ABSTRACT: Cancer-associated thrombosis (CAT), encompassing both venous thromboembolism and arterial thrombosis, contributes to up to 14% of cancer-related mortality and remains difficult to treat due to the bleeding risks of conventional anticoagulants. Protein disulfide isomerase (PDI) and its family member ERp57 (PDIA3) are thiol isomerases that regulate both arterial and venous thrombosis and are also upregulated in tumors, where they promote growth, metastasis, and immune evasion. Here, we evaluated the therapeutic potential of two thiol isomerase inhibitors-isoquercetin (ISOQ), a selective PDI inhibitor, and zafirlukast (ZAF), a broad-spectrum inhibitor of thiol isomerases such as PDI and ERp57-individually and in combination, in a xenograft model of ovarian cancer. ISOQ inhibited both platelet

SUBMITTER: Keovilay JA 

PROVIDER: S-EPMC12755188 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature